The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.

Amadori, S.; Bruno, A; Buccisano, F; Cantonetti, M; Capelli, Giovanni; Consalvo, Ma; Del Poeta, G; Del Principe Mi,; Gattei, V; Gianni, L; Lo Coco, F; Maurillo, L; Mazzone, C; Venditti, A

The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.

Authors: S. Amadori
A Bruno
F Buccisano
M Cantonetti
Giovanni Capelli
Ma Consalvo
G Del Poeta
Del Principe Mi,
V Gattei
L Gianni
F Lo Coco
L Maurillo
C Mazzone
A Venditti
Publication date: 1 January 2005
Publisher: 'Wiley'
Doi

Abstract

Clinical trials of monoclonal antibodies in combination with chemotherapy have reported previously unattained response rates in patients with B-cell chronic lymphocytic leukemia (B-CLL); however, the analysis of ZAP-70 protein and/or CD38 may explain better the discordant outcomes independent of treatment